KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Shares Issued (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Shares Issued for 17 consecutive years, with $6.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued fell 14.19% year-over-year to $6.7 million, compared with a TTM value of $14.5 million through Dec 2025, down 70.66%, and an annual FY2025 reading of $14.5 million, down 70.66% over the prior year.
  • Shares Issued was $6.7 million for Q4 2025 at Biomarin Pharmaceutical, up from $7000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $29.4 million in Q2 2024 and bottomed at $7000.0 in Q3 2025.
  • Average Shares Issued over 5 years is $13.2 million, with a median of $8.2 million recorded in 2022.
  • The sharpest move saw Shares Issued surged 174.45% in 2022, then plummeted 99.85% in 2025.
  • Year by year, Shares Issued stood at $16.3 million in 2021, then skyrocketed by 56.08% to $25.5 million in 2022, then crashed by 41.87% to $14.8 million in 2023, then plummeted by 46.9% to $7.9 million in 2024, then decreased by 14.19% to $6.7 million in 2025.
  • Business Quant data shows Shares Issued for BMRN at $6.7 million in Q4 2025, $7000.0 in Q3 2025, and $7.7 million in Q2 2025.